Akebia Therapeutics (AKBA) Misses Q4 EPS by 5c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.05), $0.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $57.62 million versus the consensus estimate of $56.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch